[Elsevier] Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-bl...

OmarElkoumi Post time 2024-4-20 13:59:12 | Show all posts |Read mode

Reward10points

Edited by OmarElkoumi at 2024-4-20 14:00

The Article Link: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00692-6/abstract

Note: Copy the whole link

2024-4-20

Please adopt

Reply

All Reply1 Show all posts

gaoblue1608 Post time 2024-4-20 13:59:13 | Show all posts

: This post has been completed
Completed attachments will be deleted within 24 hours.

Reply

OmarElkoumi Lv.3

Intermediate member

[Elsevier] Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-bl... Copy